{"id":416753,"date":"2021-01-19T08:33:33","date_gmt":"2021-01-19T13:33:33","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=416753"},"modified":"2021-01-19T08:33:33","modified_gmt":"2021-01-19T13:33:33","slug":"oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/","title":{"rendered":"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Sirtex to Pay $5 Million for a Non-Exclusive Option to Co-Promote TAVO in Patients with Checkpoint Refractory Metastatic Melanoma in the U.S. and an Additional $25 Million if the Option is Exercised<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">PENNINGTON, N.J.<\/span> and <span class=\"xn-location\">SAN DIEGO<\/span>, <span class=\"xn-chron\">Jan. 19, 2021<\/span> \/PRNewswire\/ &#8212; OncoSec Medical Incorporated (NASDAQ:ONCS) (the &#8220;Company&#8221; or &#8220;OncoSec&#8221;) today announced it entered into an agreement with Sirtex Medical, Inc. (Sirtex) granting Sirtex an option to non-exclusively co-promote the Company&#8217;s lead product candidate, TAVO\u2122 (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. By entering into this co-promotion, OncoSec intends to capitalize on both the extensive experience Sirtex has in marketing drug\/device combination products, as well as their established oncology sales force in the U.S.\u00a0 <\/p>\n<p>\n        <span class=\"xn-person\">Daniel O&#8217;Connor<\/span>, President and Chief Executive Officer of OncoSec, stated, &#8220;Sirtex is a strong company with significant experience in the sales and marketing of drug\/device combination products to treat cancer. This deal provides OnocSec with the potential to commercialize TAVO with a highly skilled U.S. sales force in this initial indication, while retaining the right to grant others the ability to do so and the flexibility to buy back the rights if warranted.&#8221;<\/p>\n<p>Under the terms of the agreement, Sirtex will pay OncoSec <span class=\"xn-money\">$5 million<\/span> for a non-exclusive option to co-promote TAVO in combination with KEYTRUDA<sup>\u00ae<\/sup>\u00a0in patients with anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. If exercised, this option would require Sirtex to pay an additional <span class=\"xn-money\">$20 million<\/span> in cash and purchase <span class=\"xn-money\">$5 million<\/span> in common stock of the Company at a market price. The option must be exercised by Sirtex within 90 days of OncoSec&#8217;s filing a Biologics License Application (BLA) with the FDA and carries a co-promote term of eight years. OncoSec reserves the right to grant others co-promotion rights, as well as the right to buy back the co-promotion rights for a certain amount determined by the remaining number of years left in the term, but not to exceed <span class=\"xn-money\">$45 million<\/span>.\u00a0\u00a0\u00a0 <\/p>\n<p>\n        <span class=\"xn-person\">Kevin Smith<\/span>, Chief Executive Officer of Sirtex, stated, &#8220;Sirtex has an established oncology sales force in the U.S. and welcomes the opportunity to leverage our resources to market TAVO\u00a0in patients with anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. We are very impressed with the progress OncoSec has made to date and believe that TAVO\u00a0\u00a0represents a viable opportunity to address this high unmet medical need.&#8221;<\/p>\n<p>If exercised, the option would require Sirtex to field a sales force to promote TAVO\u00a0among key target audiences to be agreed upon by OncoSec and Sirtex. To support these efforts, OncoSec will provide materials to help train Sirtex&#8217;s team of sales representatives. The companies will share the sales and marketing costs, with OncoSec assuming approximately two thirds of such costs and Sirtex assuming approximately one third. OncoSec will pay Sirtex a high-teens royalty on net sales in the indication in the U.S. The companies will establish a joint committee pertaining to sales and marketing activities to be undertaken, with OncoSec retaining final decision making authority for all matters relating to TAVO,\u00a0including, but not limited to, pricing, supply terms, manufacturing and clinical trials. Additionally, OncoSec shall invoice and book all sales.\u00a0 <\/p>\n<p>Sirtex is a global healthcare business with offices in the U.S., <span class=\"xn-location\">Australia<\/span>, <span class=\"xn-location\">Europe<\/span> and <span class=\"xn-location\">Asia<\/span>, working to improve outcomes in people with cancer. Sirtex&#8217;s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres<sup>\u00ae<\/sup><span class=\"xn-money\">Y-90<\/span> resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,400 medical centers in over 50 countries. For more information, visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3040696-1&amp;h=3801135344&amp;u=http%3A%2F%2Fwww.sirtex.com%2F&amp;a=www.sirtex.com\" rel=\"nofollow noopener noreferrer\">www.sirtex.com<\/a>.<\/p>\n<p>\n        <b>About TAVO<\/b><br \/>\n        <sup>\u2122<\/sup>\u00a0<br \/>OncoSec&#8217;s gene therapy technology combines TAVO\u00a0\u00a0(tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), with an intra-tumoral electroporation gene delivery platform to achieve endogenous IL-12 production in the tumor microenvironment that enables the immune system to target and attack tumors throughout the body. TAVO \u00a0has demonstrated a local and systemic anti-tumor response in several clinical trials, including the pivotal Phase <span class=\"xn-money\">2b<\/span> trial KEYNOTE-695 for metastatic melanoma and the KEYNOTE-890 Phase 2 trial in triple negative breast cancer (TNBC). TAVO\u2122\u00a0has received both Orphan Drug and Fast-Track Designation by the U.S.\u00a0 Food &amp; Drug Administration for the treatment of metastatic melanoma.<\/p>\n<p>\n        <b>About OncoSec Medical Incorporated<br \/><\/b>OncoSec Medical Incorporated (the &#8220;Company,&#8221; &#8220;OncoSec,&#8221; &#8220;we&#8221; or &#8220;our&#8221;) is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body&#8217;s immune system to target and attack cancer. OncoSec&#8217;s lead immunotherapy investigational product candidate \u2013 TAVO \u00a0(tavokinogene telseplasmid) \u2013 enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO \u00a0as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO \u00a0have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile, warranting further development. In addition to TAVO, \u00a0OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3040696-1&amp;h=1105914179&amp;u=http%3A%2F%2Fwww.oncosec.com%2F&amp;a=www.oncosec.com\" rel=\"nofollow noopener noreferrer\">www.oncosec.com<\/a>.\u00a0<\/p>\n<p>TAVO\u2122 is a trademark of OncoSec Medical Incorporated.<\/p>\n<p>KEYTRUDA<sup>\u00ae<\/sup>\u00a0is a registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.<\/p>\n<p>SIR-Spheres<sup>\u00ae<\/sup> is a registered trademark of Sirtex SIR-Spheres Pty Ltd.<\/p>\n<p>\n        <b>Risk Factors and Forward-Looking Statements<br \/><\/b>This release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company&#8217;s current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company&#8217;s control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and &#8220;would&#8221; and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward- looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission (&#8220;SEC&#8221;). In particular, you should be aware that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, the impact of COVID-19 on the supply of our candidates or the initiation or completion of clinical trials and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended <span class=\"xn-chron\">July 31, 2020<\/span> and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC&#8217;s website <a href=\"http:\/\/www.sec.gov\" rel=\"nofollow\">www.sec.gov<\/a>), as well as other factors described from time to time in the Company&#8217;s filings with the SEC.<\/p>\n<p>\n        <b>Company Contact<br \/><\/b><br \/>\n        <span class=\"xn-person\">Kim Jaffe<\/span>, Ph.D.<br \/>Assistant Vice President, Business Development &amp; Operations\u00a0\u00a0<br \/>+1-858-210-7330 <br \/><a target=\"_blank\" href=\"mailto:kjaffe@oncosec.com\" rel=\"nofollow noopener noreferrer\">kjaffe@oncosec.com<\/a>\u00a0 <\/p>\n<p>\n        <b>Media Contact<br \/><\/b><br \/>\n        <span class=\"xn-person\">Patrick Bursey<\/span><br \/>\n        <br \/>LifeSci Communications<br \/>+1-646-970-4688<br \/><a target=\"_blank\" href=\"mailto:pbursey@lifescicomms.com\" rel=\"nofollow noopener noreferrer\">pbursey@lifescicomms.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder7215\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/686236\/oncosec_logo_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/686236\/oncosec_logo_Logo.jpg\" title=\"OncoSec Medical Incorporated logo (PRNewsfoto\/OncoSec Medical Incorporated)\" alt=\"OncoSec Medical Incorporated logo (PRNewsfoto\/OncoSec Medical Incorporated)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA52258&amp;sd=2021-01-19\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo-301210487.html\">http:\/\/www.prnewswire.com\/news-releases\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo-301210487.html<\/a><\/p>\n<p>SOURCE  OncoSec Medical Incorporated<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA52258&amp;Transmission_Id=202101190830PR_NEWS_USPR_____LA52258&amp;DateId=20210119\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sirtex to Pay $5 Million for a Non-Exclusive Option to Co-Promote TAVO in Patients with Checkpoint Refractory Metastatic Melanoma in the U.S. and an Additional $25 Million if the Option is Exercised PR Newswire PENNINGTON, N.J. and SAN DIEGO, Jan. 19, 2021 \/PRNewswire\/ &#8212; OncoSec Medical Incorporated (NASDAQ:ONCS) (the &#8220;Company&#8221; or &#8220;OncoSec&#8221;) today announced it entered into an agreement with Sirtex Medical, Inc. (Sirtex) granting Sirtex an option to non-exclusively co-promote the Company&#8217;s lead product candidate, TAVO\u2122 (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. By entering into this co-promotion, OncoSec intends to capitalize on both the extensive experience Sirtex has in marketing drug\/device combination products, as well as their established oncology sales force in the U.S.\u00a0 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-416753","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sirtex to Pay $5 Million for a Non-Exclusive Option to Co-Promote TAVO in Patients with Checkpoint Refractory Metastatic Melanoma in the U.S. and an Additional $25 Million if the Option is Exercised PR Newswire PENNINGTON, N.J. and SAN DIEGO, Jan. 19, 2021 \/PRNewswire\/ &#8212; OncoSec Medical Incorporated (NASDAQ:ONCS) (the &#8220;Company&#8221; or &#8220;OncoSec&#8221;) today announced it entered into an agreement with Sirtex Medical, Inc. (Sirtex) granting Sirtex an option to non-exclusively co-promote the Company&#8217;s lead product candidate, TAVO\u2122 (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. By entering into this co-promotion, OncoSec intends to capitalize on both the extensive experience Sirtex has in marketing drug\/device combination products, as well as their established oncology sales force in the U.S.\u00a0 &hellip; Continue reading &quot;OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-19T13:33:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/686236\/oncosec_logo_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122\",\"datePublished\":\"2021-01-19T13:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\\\/\"},\"wordCount\":1379,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/686236\\\/oncosec_logo_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\\\/\",\"name\":\"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/686236\\\/oncosec_logo_Logo.jpg\",\"datePublished\":\"2021-01-19T13:33:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/686236\\\/oncosec_logo_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/686236\\\/oncosec_logo_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/","og_locale":"en_US","og_type":"article","og_title":"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122 - Market Newsdesk","og_description":"Sirtex to Pay $5 Million for a Non-Exclusive Option to Co-Promote TAVO in Patients with Checkpoint Refractory Metastatic Melanoma in the U.S. and an Additional $25 Million if the Option is Exercised PR Newswire PENNINGTON, N.J. and SAN DIEGO, Jan. 19, 2021 \/PRNewswire\/ &#8212; OncoSec Medical Incorporated (NASDAQ:ONCS) (the &#8220;Company&#8221; or &#8220;OncoSec&#8221;) today announced it entered into an agreement with Sirtex Medical, Inc. (Sirtex) granting Sirtex an option to non-exclusively co-promote the Company&#8217;s lead product candidate, TAVO\u2122 (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. By entering into this co-promotion, OncoSec intends to capitalize on both the extensive experience Sirtex has in marketing drug\/device combination products, as well as their established oncology sales force in the U.S.\u00a0 &hellip; Continue reading \"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-19T13:33:33+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/686236\/oncosec_logo_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122","datePublished":"2021-01-19T13:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/"},"wordCount":1379,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/686236\/oncosec_logo_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/","name":"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/686236\/oncosec_logo_Logo.jpg","datePublished":"2021-01-19T13:33:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/686236\/oncosec_logo_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/686236\/oncosec_logo_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncosec-enters-into-option-agreement-with-sirtex-medical-to-co-promote-tavo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=416753"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416753\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=416753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=416753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=416753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}